Vivanza Biosciences Ltd Stock Price Today (NSE: VIVANZA)
Fundamental Score
Vivanza Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vivanza Biosciences Ltd share price today is ₹1.89, up +0.00% on NSE/BSE as of 7 August 2026. Vivanza Biosciences Ltd (VIVANZA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹7.16 (Cr). The 52-week high for VIVANZA share price is ₹2.72 and the 52-week low is ₹1.52. At a P/E ratio of 18.36x, VIVANZA is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.38% and a debt-to-equity ratio of 2.34.
Vivanza Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Vivanza Biosciences Ltd share price chart: -8.00% return over the past month. 52-week high ₹2.72, 52-week low ₹1.52.
Vivanza Biosciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1.82 | ₹1.89 | ₹1.82 | ₹1.84 | 26.06K (Cr) | |
| ₹1.94 | ₹1.94 | ₹1.90 | ₹1.94 | 8.92K (Cr) | |
| ₹1.97 | ₹1.97 | ₹1.94 | ₹1.94 | 39.69K (Cr) | |
| ₹1.80 | ₹1.81 | ₹1.80 | ₹1.81 | 3.52K (Cr) | |
| ₹1.95 | ₹1.95 | ₹1.80 | ₹1.80 | 36.73K (Cr) | |
| ₹1.76 | ₹1.97 | ₹1.76 | ₹1.82 | 11.34K (Cr) | |
| ₹1.75 | ₹1.79 | ₹1.75 | ₹1.76 | 34.43K (Cr) | |
| ₹1.79 | ₹1.80 | ₹1.79 | ₹1.80 | 2.23K (Cr) | |
| ₹1.85 | ₹1.91 | ₹1.75 | ₹1.79 | 4.79K (Cr) | |
| ₹1.87 | ₹1.87 | ₹1.85 | ₹1.85 | 5.26K (Cr) |
Vivanza Biosciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1.95 | ₹2.00 | ₹1.75 | ₹1.84 | -5.64% | |
| ₹1.74 | ₹2.13 | ₹1.52 | ₹1.82 | +4.60% | |
| ₹2.01 | ₹2.15 | ₹1.74 | ₹1.74 | -13.43% | |
| ₹1.84 | ₹2.13 | ₹1.82 | ₹2.07 | +12.50% | |
| ₹2.04 | ₹2.04 | ₹1.75 | ₹1.76 | -13.73% | |
| ₹2.09 | ₹2.18 | ₹2.02 | ₹2.04 | -2.39% | |
| ₹2.20 | ₹2.31 | ₹1.98 | ₹2.06 | -6.36% | |
| ₹2.20 | ₹2.31 | ₹2.00 | ₹2.20 | +0.00% | |
| ₹1.96 | ₹2.72 | ₹1.95 | ₹2.20 | +12.24% | |
| ₹2.04 | ₹2.25 | ₹1.90 | ₹1.96 | -3.92% | |
| ₹2.10 | ₹2.22 | ₹1.98 | ₹2.04 | -2.86% | |
| ₹2.11 | ₹2.18 | ₹1.98 | ₹2.05 | -2.84% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vivanza Biosciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vivanza Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VIVANZA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 18.36 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (55.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (1225.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (63.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (37.28% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (37.28% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (9.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.11%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (1.15%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Elevated Debt Levels (D/E: 2.34)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-1.69 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (20.02%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vivanza Biosciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vivanza Biosciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vivanza Biosciences LtdVivanza Bioscie...Selected✓ VIVANZA • 530057 | 51.5/100 | ₹1.89₹2 | ₹7.16₹7.16 | 18.36Average 18.4 Average | 9.38%Poor 9.38% Poor | 6.11%Poor 6.11% Poor | 2.34Poor 2.3 Poor | 37.28%Excellent 37.28% Excellent | 63.60%Excellent 63.60% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Vivanza Biosciences Ltd PE Ratio History
Historical price-to-earnings ratio for VIVANZA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.14 | ₹3.42 | 24.4x |
| FY 2023 | ₹0.15 | ₹10.77 | 71.8x |
| FY 2022 | ₹0.08 | ₹15.60 | 188x |
| FY 2021 | ₹0.02 | ₹17.91 | 942.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vivanza Biosciences Ltd Quarterly Performance
Latest quarterly metrics for VIVANZA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
1225.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
55.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
63.60%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
37.28%
Compounded annual net profit growth over 5 years
Vivanza Biosciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VIVANZA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vivanza Biosciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vivanza Biosciences Ltd (VIVANZA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vivanza Biosciences Ltd
About VIVANZA (Vivanza Biosciences Ltd)
Vivanza Biosciences Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian healthcare landscape. From its base in Ahmedabad, the company channels its energies into the ...meticulous creation of a diverse portfolio of medical products. Vivanza operates at the intersection of research, development, and production, focusing on fulfilling critical needs within the medical community. They are committed to crafting products that meet rigorous quality standards, essential for patient well-being. While maintaining a commitment to traditional manufacturing practices, they also embrace modern techniques to improve efficiency and expand product availability, solidifying their position as a reliable source within the Indian pharmaceutical industry. The company's product line extends beyond just pharmaceuticals, showcasing a commitment to comprehensive medical supplies. Vivanza Biosciences provides a variety of gloves, from the widely used latex surgical and examination options, to latex-free alternatives catering to individuals with specific sensitivities. This variety demonstrates an awareness of the evolving needs of healthcare providers and a dedication to offering solutions for a wide range of medical settings. By producing surgical products alongside its pharmaceutical offerings, Vivanza aims to provide a holistic approach to patient care, catering to both preventative and interventional needs. This diverse approach makes them a valued contributor to the accessibility of essential medical products in the Indian market. With a history dating back to 1982, Vivanza Biosciences Ltd leverages decades of experience within the pharmaceutical sector. This established presence gives them a unique perspective on the evolving challenges and opportunities within the Indian healthcare system. Their consistent focus on manufacturing and distributing quality products has helped them build lasting relationships with healthcare providers and patients. While constantly striving for innovation and improvement, they remain grounded in their commitment to reliability and accessibility. As the Indian pharmaceutical landscape continues to advance, Vivanza Biosciences is strategically positioned to adapt and contribute meaningfully to the nation's healthcare needs.
Company Details
Key Leadership
Latest News
VIVANZA Share Price: Frequently Asked Questions
What is the current share price of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd (VIVANZA) trades at ₹1.89 on NSE and BSE. Market cap ₹7.16 (Cr). Educational data only.
What is the P/E ratio of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd has a P/E of 18.36x vs industry average 34.89x.
What is the Bull Run score for Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd has a Bull Run score of 51.5/100 based on 25+ financial parameters.
Does Vivanza Biosciences Ltd pay dividends?
Vivanza Biosciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd has ROE of 9.38%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd has debt-to-equity of 2.34.
Is Vivanza Biosciences Ltd a good investment?
Bull Run gives Vivanza Biosciences Ltd a score of 51.5/100. This is not investment advice — consult a SEBI-registered advisor.